Traws Pharma, Inc. (TRAW) — 8-K Filings

8-K Filings (47)

• Traws Pharma Files 8-K: Agreements and Equity Sales — Apr 15, 2026 Risk: medium
  Traws Pharma, Inc. filed an 8-K on April 15, 2026, reporting a material definitive agreement, unregistered sales of equity securities, and other events. The fil
• Traws Pharma Files 8-K — Dec 17, 2025 Risk: low
  Traws Pharma, Inc. (formerly Onconova Therapeutics, Inc.) filed an 8-K on December 17, 2025, reporting other events and financial statements. The company, incor
• 8-K Filing — Dec 16, 2025
• Traws Pharma Files 8-K on Officer Changes & Shareholder Votes — Nov 28, 2025 Risk: medium
  Traws Pharma, Inc. filed an 8-K on November 28, 2025, reporting events as of November 21, 2025. The filing covers the departure of directors or certain officers
• Traws Pharma Files 8-K on Financials — Nov 13, 2025 Risk: low
  Traws Pharma, Inc. (formerly Onconova Therapeutics, Inc.) filed an 8-K on November 13, 2025, reporting on its results of operations and financial condition. The
• Traws Pharma Reports Director/Officer Changes — Oct 17, 2025 Risk: medium
  Traws Pharma, Inc. (formerly Onconova Therapeutics, Inc.) filed an 8-K on October 17, 2025, reporting changes effective October 12, 2025. The filing covers the
• Traws Pharma Files 8-K: Other Events & Exhibits — Oct 14, 2025 Risk: low
  Traws Pharma, Inc. filed an 8-K on October 14, 2025, reporting "Other Events" and "Financial Statements and Exhibits." The company, formerly known as Onconova T
• Traws Pharma Reports Officer/Director Changes & Compensatory Info — Oct 6, 2025 Risk: medium
  Traws Pharma, Inc. (formerly Onconova Therapeutics, Inc.) filed an 8-K on October 6, 2025, reporting events as of October 1, 2025. The filing covers the departu
• Traws Pharma Enters Definitive Agreement, Completes Asset Deal — Sep 12, 2025 Risk: medium
  Traws Pharma, Inc. (formerly Onconova Therapeutics, Inc.) announced on September 9, 2025, the entry into a material definitive agreement and the completion of a
• Traws Pharma Files 8-K — Aug 18, 2025 Risk: low
  Traws Pharma, Inc. (formerly Onconova Therapeutics, Inc.) filed an 8-K on August 18, 2025, reporting on events including a Regulation FD Disclosure, Other Event
• 8-K Filing — Aug 14, 2025
• Traws Pharma Director Departs, New Director Appointed — Jul 3, 2025 Risk: low
  Traws Pharma, Inc. announced on July 2, 2025, the departure of Director Dr. Jonathan R. T. Macarthur and the appointment of Dr. David J. E. Macarthur as a new d
• 8-K Filing — Jun 30, 2025
• Traws Pharma Files 8-K — Jun 3, 2025 Risk: low
  Traws Pharma, Inc. (formerly Onconova Therapeutics, Inc.) filed an 8-K on June 3, 2025, reporting on other events and financial statements. The company, incorpo
• 8-K Filing — May 27, 2025
• 8-K Filing — May 19, 2025
• Traws Pharma Files 8-K on Financials — May 15, 2025 Risk: low
  Traws Pharma, Inc. filed an 8-K on May 15, 2025, reporting on its results of operations and financial condition. The filing also includes Regulation FD disclosu
• Traws Pharma Reports Officer/Director Changes & Compensation — Apr 18, 2025 Risk: medium
  Traws Pharma, Inc. (formerly Onconova Therapeutics, Inc.) filed an 8-K on April 18, 2025, reporting changes effective April 15, 2025. The filing indicates a dep
• Traws Pharma Files 8-K — Apr 7, 2025 Risk: low
  Traws Pharma, Inc. filed an 8-K on April 7, 2025, reporting "Other Events" and "Financial Statements and Exhibits." The company, formerly known as Onconova Ther
• 8-K Filing — Mar 31, 2025
• Traws Pharma Files 8-K on Officer Changes & Financials — Mar 28, 2025 Risk: medium
  Traws Pharma, Inc. filed an 8-K on March 28, 2025, reporting on the departure of directors or certain officers, election of directors, appointment of certain of
• Traws Pharma Files 8-K — Mar 25, 2025 Risk: low
  Traws Pharma, Inc. filed an 8-K on March 25, 2025, reporting other events and financial statements. The company, formerly known as Onconova Therapeutics, Inc.,
• Traws Pharma Files 8-K — Mar 24, 2025 Risk: low
  Traws Pharma, Inc. filed an 8-K on March 24, 2025, reporting other events and financial statements/exhibits. The company, formerly known as Onconova Therapeutic
• Traws Pharma Files 8-K — Mar 21, 2025 Risk: low
  Traws Pharma, Inc. filed an 8-K on March 21, 2025, reporting other events and financial statements. The company, formerly known as Onconova Therapeutics, Inc.,
• Traws Pharma Files 8-K for Material Agreement — Mar 10, 2025 Risk: medium
  Traws Pharma, Inc. (formerly Onconova Therapeutics, Inc.) filed an 8-K on March 10, 2025, reporting the entry into a material definitive agreement and the filin
• Traws Pharma Files 8-K — Mar 3, 2025 Risk: low
  Traws Pharma, Inc. filed an 8-K on March 3, 2025, reporting other events and financial statements. The company, formerly known as Onconova Therapeutics, Inc., i
• Traws Pharma Files 8-K with Regulatory Updates — Feb 28, 2025 Risk: low
  Traws Pharma, Inc. filed an 8-K on February 28, 2025, reporting events that occurred on February 25, 2025. The filing includes information related to Regulation
• Traws Pharma Enters Material Definitive Agreement — Feb 19, 2025 Risk: medium
  Traws Pharma, Inc. entered into a material definitive agreement on February 18, 2025. The filing also includes financial statements and exhibits related to this
• Traws Pharma, Inc. Files 8-K — Feb 18, 2025 Risk: low
  On February 18, 2025, Traws Pharma, Inc. (formerly Onconova Therapeutics, Inc.) filed an 8-K report. The filing indicates a change in the company's name and pot
• Traws Pharma Announces Board & Executive Changes — Feb 7, 2025 Risk: medium
  Traws Pharma, Inc. announced on February 5, 2025, a change in its board of directors and executive compensation arrangements. The filing details the departure o
• Traws Pharma, Inc. Files 8-K — Jan 23, 2025 Risk: low
  On January 23, 2025, Traws Pharma, Inc. (formerly Onconova Therapeutics, Inc.) filed an 8-K report. The filing indicates the company is incorporated in Delaware
• Traws Pharma Files 8-K: Agreements, Equity Sales Reported — Dec 31, 2024 Risk: medium
  Traws Pharma, Inc. (formerly Onconova Therapeutics, Inc.) filed an 8-K on December 29, 2024, reporting the entry into a material definitive agreement, unregiste
• Traws Pharma Shuffles Leadership, Appoints New Directors — Dec 20, 2024 Risk: medium
  Traws Pharma, Inc. announced on December 16, 2024, the departure of Dr. Steven A. Deitcher as Chief Medical Officer and the appointment of Dr. Richard E. G. Smi
• Traws Pharma Faces Delisting Concerns — Nov 22, 2024 Risk: high
  Traws Pharma, Inc. (formerly Onconova Therapeutics, Inc.) filed an 8-K on November 22, 2024, reporting a notice of delisting or failure to satisfy continued lis
• Traws Pharma Files 8-K on Financials — Nov 14, 2024 Risk: low
  Traws Pharma, Inc. filed an 8-K on November 14, 2024, reporting on its results of operations and financial condition. The filing also includes financial stateme
• Traws Pharma Files 8-K on Shareholder Votes & Other Events — Nov 1, 2024 Risk: medium
  Traws Pharma, Inc. (formerly Onconova Therapeutics, Inc.) filed an 8-K on November 1, 2024, reporting on matters submitted to a vote of security holders and oth
• Traws Pharma Faces Delisting Concerns — Sep 27, 2024 Risk: high
  Traws Pharma, Inc. (formerly Onconova Therapeutics, Inc.) filed an 8-K on September 27, 2024, reporting a notice of delisting or failure to satisfy a continued
• Traws Pharma Reports Director Changes & Shareholder Votes — Sep 17, 2024 Risk: medium
  Traws Pharma, Inc. (formerly Onconova Therapeutics, Inc.) filed an 8-K on September 17, 2024, reporting several key events. These include changes in directors a
• Traws Pharma Faces Nasdaq Delisting, Seeks Compliance — Aug 23, 2024 Risk: high
  Traws Pharma, Inc. (formerly Onconova Therapeutics, Inc.) filed an 8-K on August 23, 2024, to report its failure to meet the continued listing standards of the
• Traws Pharma Files 8-K on Financials — Aug 15, 2024 Risk: low
  Traws Pharma, Inc. filed an 8-K on August 15, 2024, reporting on its results of operations and financial condition. The filing also includes financial statement
• Traws Pharma Appoints BDO USA as New Auditor — Jul 19, 2024 Risk: low
  On July 16, 2024, Traws Pharma, Inc. (formerly Onconova Therapeutics, Inc.) announced a change in its certifying accountant. The company has appointed BDO USA,
• Traws Pharma Changes Fiscal Year End — Jun 28, 2024 Risk: low
  Traws Pharma, Inc. filed an 8-K on June 28, 2024, reporting a change in its fiscal year end to December 31st, effective as of June 26, 2024. The company, previo
• Traws Pharma Appoints New Director — Jun 21, 2024 Risk: low
  Traws Pharma, Inc. announced on June 17, 2024, a change in its board of directors. Specifically, Dr. Steven A. Deitcher has been appointed as a new director. Th
• Traws Pharma Changes Certifying Accountant — May 22, 2024 Risk: low
  Traws Pharma, Inc. (formerly Onconova Therapeutics, Inc.) filed an 8-K on May 22, 2024, reporting a change in its certifying accountant as of May 17, 2024. The
• Traws Pharma Files 8-K on Operations — May 16, 2024 Risk: low
  Traws Pharma, Inc. (formerly Onconova Therapeutics, Inc.) filed an 8-K on May 16, 2024, reporting on its results of operations and financial condition. The comp
• Traws Pharma Files 8-K for Disclosure and Exhibits — Apr 16, 2024 Risk: low
  Traws Pharma, Inc. (formerly Onconova Therapeutics, Inc.) filed an 8-K on April 16, 2024, to report a Regulation FD Disclosure and Financial Statements and Exhi
• Traws Pharma Acquires 03 Life Sciences, Names New CMO — Apr 4, 2024 Risk: medium
  Traws Pharma, Inc. (formerly Onconova Therapeutics, Inc.) announced on April 1, 2024, the completion of its acquisition of 03 Life Sciences. This transaction in

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX